. 2014 May 21;16(7):421. doi: 10.1007/s11883-014-0421-5

Table 3.

Copeptin studies in populations with high MI prevalence

Study	MI prevalence	Troponin assay	Copeptin assay	NPV^a	Comments
Afzali et al. [16•]	CPU population (single center). AMI 46.5 %(107/230), NSTEMI 36.1 % (83/230)	TnI-Ultra (Siemens Healthcare) cutoff <0.04 ng/ml (99th percentile)	Copeptin KRYPTOR (Thermo Fisher B·R·A·H·M·S) <14 pmol/l	97.3 %	13 % of patients with a GRACE score greater than 140. Onset of symptoms after more than 12 h in 37.8 % of patients
Sukul et al. [17•]	Single-center study, setting not reported. AMI 25.7 % (104/405), NSTEMI 22.4 % (91/405)	Local cTnI (Centaur, Siemens Healthcare)cutoff 100 ng/l. Sensitive cTnI (TnI-Ultra, Siemens Healthcare) cutoff 40 ng/l (99th percentile)	Copeptin KRYPTOR (Thermo Fisher B·R·A·H·M·S) 14 pmol/l	cTnI alone 92 % (89-95 %), sensitive TnI alone 98 % (95-99 %), sensitive TnI plus copeptin 97 % (94-99 %) (for all AMI). In early presenters (<6 h), sensitive TnI 100 % (96-100 %), sensitive TnI plus copeptin 100 % (95-100 %)	No analysis of NSTEMI patients only
Eggers et al. [18•]	CPU population, NSTEMI 35.6 % (128/360) FAST II: 2000–2001 FASTER I: 2002-2003	hsTnT (Roche Diagnostics) 14 ng/l. NSTEMI diagnosis based on routine TnI result (Stratus CS, Siemens Healthcare)	Ultrasensitive copeptin KRYPTOR PLUS (Thermo Fisher B·R·A·H·M·S) >14 pmol/l	hsTnT alone 86.5 % (81.0-90.0 %),hsTnT plus copeptin 89 % (83.1-93.3 %)	Pooled population of patients included in the FAST II and FASTER I studies with available results for biomarkers, only NSTEMI and symptom onset <8 h

Study

MI prevalence

Troponin assay

Copeptin assay

NPV^a

Comments

Afzali et al. [16•]

CPU population (single center). AMI 46.5 %(107/230), NSTEMI 36.1 % (83/230)

TnI-Ultra (Siemens Healthcare) cutoff <0.04 ng/ml (99th percentile)

Copeptin KRYPTOR (Thermo Fisher B·R·A·H·M·S) <14 pmol/l

97.3 %

13 % of patients with a GRACE score greater than 140. Onset of symptoms after more than 12 h in 37.8 % of patients

Sukul et al. [17•]

Single-center study, setting not reported. AMI 25.7 % (104/405), NSTEMI 22.4 % (91/405)

Local cTnI (Centaur, Siemens Healthcare)cutoff 100 ng/l. Sensitive cTnI (TnI-Ultra, Siemens Healthcare) cutoff 40 ng/l (99th percentile)

Copeptin KRYPTOR (Thermo Fisher B·R·A·H·M·S) 14 pmol/l

cTnI alone 92 % (89-95 %), sensitive TnI alone 98 % (95-99 %), sensitive TnI plus copeptin 97 % (94-99 %) (for all AMI). In early presenters (<6 h), sensitive TnI 100 % (96-100 %), sensitive TnI plus copeptin 100 % (95-100 %)

No analysis of NSTEMI patients only

Eggers et al. [18•]

CPU population, NSTEMI 35.6 % (128/360)

FAST II: 2000–2001

FASTER I: 2002-2003

hsTnT (Roche Diagnostics) 14 ng/l. NSTEMI diagnosis based on routine TnI result (Stratus CS, Siemens Healthcare)

Ultrasensitive copeptin KRYPTOR PLUS (Thermo Fisher B·R·A·H·M·S) >14 pmol/l

hsTnT alone 86.5 % (81.0-90.0 %),hsTnT plus copeptin 89 % (83.1-93.3 %)

Pooled population of patients included in the FAST II and FASTER I studies with available results for biomarkers, only NSTEMI and symptom onset <8 h

GRACE Global Registry of Acute Coronary Events

^aNPV for marker combination if not indicated otherwise.